Laura Pyle
Concepts (652)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 99 | 2024 | 3361 | 6.290 |
Why?
| Blood Glucose | 60 | 2024 | 1946 | 3.550 |
Why?
| Insulin Resistance | 37 | 2024 | 1184 | 2.750 |
Why?
| Diabetes Mellitus, Type 2 | 33 | 2024 | 2179 | 2.490 |
Why?
| Blood Glucose Self-Monitoring | 30 | 2024 | 534 | 2.400 |
Why?
| Diabetic Nephropathies | 19 | 2022 | 289 | 2.040 |
Why?
| Polycystic Ovary Syndrome | 13 | 2021 | 157 | 1.810 |
Why?
| Adolescent | 136 | 2024 | 18483 | 1.740 |
Why?
| Insulin | 29 | 2024 | 2170 | 1.690 |
Why?
| Child | 114 | 2024 | 19137 | 1.380 |
Why?
| Hypoglycemic Agents | 23 | 2024 | 1035 | 1.310 |
Why?
| Hypoglycemia | 10 | 2024 | 401 | 1.270 |
Why?
| Obesity | 22 | 2022 | 2751 | 1.250 |
Why?
| Insulin Infusion Systems | 13 | 2023 | 306 | 1.210 |
Why?
| Diabetic Ketoacidosis | 7 | 2022 | 168 | 1.140 |
Why?
| Metformin | 11 | 2021 | 295 | 1.120 |
Why?
| Young Adult | 70 | 2024 | 10799 | 1.100 |
Why?
| Humans | 200 | 2024 | 119032 | 1.050 |
Why?
| Female | 151 | 2024 | 61588 | 1.050 |
Why?
| Hyperglycemia | 8 | 2022 | 316 | 0.940 |
Why?
| Male | 126 | 2024 | 57818 | 0.910 |
Why?
| Glomerular Filtration Rate | 19 | 2024 | 684 | 0.910 |
Why?
| RNAi Therapeutics | 1 | 2021 | 4 | 0.830 |
Why?
| Hyperoxaluria, Primary | 1 | 2021 | 15 | 0.820 |
Why?
| Pancreas, Artificial | 1 | 2021 | 71 | 0.760 |
Why?
| Diabetic Angiopathies | 7 | 2019 | 261 | 0.740 |
Why?
| Puberty | 6 | 2022 | 144 | 0.730 |
Why?
| Pediatric Obesity | 7 | 2021 | 524 | 0.720 |
Why?
| Glucose Clamp Technique | 10 | 2020 | 195 | 0.680 |
Why?
| Software | 2 | 2021 | 613 | 0.660 |
Why?
| Albuminuria | 10 | 2022 | 196 | 0.660 |
Why?
| Adult | 65 | 2024 | 31525 | 0.660 |
Why?
| Biomarkers | 21 | 2022 | 3590 | 0.630 |
Why?
| Case-Control Studies | 23 | 2022 | 3173 | 0.630 |
Why?
| Mitochondria, Muscle | 5 | 2021 | 97 | 0.610 |
Why?
| Cardiovascular Diseases | 10 | 2024 | 1802 | 0.580 |
Why?
| Technology | 6 | 2023 | 83 | 0.580 |
Why?
| Islets of Langerhans | 6 | 2023 | 739 | 0.570 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 968 | 0.570 |
Why?
| Cystic Fibrosis | 6 | 2023 | 965 | 0.560 |
Why?
| Sleep | 7 | 2024 | 660 | 0.560 |
Why?
| Testosterone | 6 | 2022 | 351 | 0.550 |
Why?
| Self-Management | 3 | 2023 | 136 | 0.550 |
Why?
| Body Mass Index | 16 | 2024 | 2092 | 0.530 |
Why?
| Glycopeptides | 4 | 2021 | 58 | 0.530 |
Why?
| Kidney | 13 | 2024 | 1357 | 0.530 |
Why?
| Glucose Tolerance Test | 10 | 2023 | 368 | 0.530 |
Why?
| Glycerol | 1 | 2015 | 88 | 0.530 |
Why?
| Prediabetic State | 5 | 2022 | 234 | 0.530 |
Why?
| Klinefelter Syndrome | 3 | 2022 | 53 | 0.530 |
Why?
| Cross-Sectional Studies | 26 | 2023 | 4552 | 0.520 |
Why?
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 540 | 0.520 |
Why?
| Adipose Tissue | 7 | 2021 | 606 | 0.480 |
Why?
| Child, Preschool | 30 | 2024 | 9493 | 0.480 |
Why?
| Insulin-Secreting Cells | 4 | 2022 | 330 | 0.480 |
Why?
| Algorithms | 4 | 2023 | 1543 | 0.460 |
Why?
| Pregnancy in Diabetics | 3 | 2020 | 88 | 0.450 |
Why?
| Coronary Artery Disease | 5 | 2019 | 648 | 0.450 |
Why?
| Vascular Stiffness | 4 | 2019 | 425 | 0.430 |
Why?
| Diabetic Cardiomyopathies | 4 | 2016 | 39 | 0.430 |
Why?
| Vascular Calcification | 4 | 2019 | 123 | 0.420 |
Why?
| Diabetes Mellitus | 4 | 2023 | 945 | 0.420 |
Why?
| Muscle, Skeletal | 8 | 2021 | 1523 | 0.410 |
Why?
| Sex Chromosomes | 2 | 2022 | 48 | 0.400 |
Why?
| Autoantibodies | 9 | 2023 | 1335 | 0.400 |
Why?
| Overweight | 6 | 2022 | 502 | 0.380 |
Why?
| Adiponectin | 3 | 2016 | 226 | 0.370 |
Why?
| Uric Acid | 4 | 2021 | 354 | 0.370 |
Why?
| Risk Factors | 23 | 2022 | 9003 | 0.370 |
Why?
| Colorado | 17 | 2023 | 4196 | 0.370 |
Why?
| Prospective Studies | 15 | 2023 | 6477 | 0.370 |
Why?
| Patient Education as Topic | 3 | 2016 | 699 | 0.360 |
Why?
| Osteoporotic Fractures | 2 | 2020 | 51 | 0.360 |
Why?
| Hospitals, Pediatric | 6 | 2019 | 505 | 0.350 |
Why?
| Uromodulin | 2 | 2019 | 28 | 0.340 |
Why?
| Calcinosis | 4 | 2015 | 282 | 0.340 |
Why?
| Triglycerides | 5 | 2022 | 521 | 0.330 |
Why?
| Fatty Acids, Nonesterified | 4 | 2018 | 167 | 0.330 |
Why?
| Psychology, Adolescent | 1 | 2009 | 63 | 0.330 |
Why?
| Fasting | 4 | 2019 | 264 | 0.330 |
Why?
| Infant | 19 | 2024 | 8295 | 0.320 |
Why?
| Retrospective Studies | 23 | 2024 | 12990 | 0.320 |
Why?
| Fructosamine | 3 | 2018 | 21 | 0.320 |
Why?
| Creatinine | 9 | 2022 | 491 | 0.310 |
Why?
| Glucose | 7 | 2023 | 954 | 0.310 |
Why?
| Renal Insufficiency | 2 | 2022 | 150 | 0.300 |
Why?
| Lipolysis | 2 | 2018 | 42 | 0.300 |
Why?
| Metabolic Syndrome | 3 | 2020 | 394 | 0.300 |
Why?
| Disease Progression | 10 | 2021 | 2490 | 0.300 |
Why?
| Time Factors | 12 | 2022 | 6414 | 0.300 |
Why?
| Serum Albumin | 3 | 2018 | 147 | 0.300 |
Why?
| Electronic Health Records | 4 | 2023 | 830 | 0.290 |
Why?
| Sodium-Glucose Transporter 2 | 3 | 2023 | 21 | 0.290 |
Why?
| Coronary Vessels | 3 | 2019 | 233 | 0.290 |
Why?
| Fatty Liver | 2 | 2021 | 253 | 0.280 |
Why?
| Adiposity | 4 | 2020 | 516 | 0.280 |
Why?
| Exercise Tolerance | 3 | 2017 | 233 | 0.270 |
Why?
| Deoxyglucose | 2 | 2016 | 46 | 0.270 |
Why?
| Circadian Rhythm | 2 | 2019 | 401 | 0.270 |
Why?
| Body Composition | 6 | 2021 | 653 | 0.270 |
Why?
| Bone Density | 5 | 2022 | 449 | 0.260 |
Why?
| Actigraphy | 4 | 2019 | 80 | 0.260 |
Why?
| Atherosclerosis | 2 | 2022 | 346 | 0.260 |
Why?
| Apolipoproteins B | 2 | 2015 | 44 | 0.260 |
Why?
| Autism Spectrum Disorder | 2 | 2020 | 324 | 0.260 |
Why?
| Trauma Centers | 3 | 2016 | 388 | 0.250 |
Why?
| Femur Neck | 2 | 2022 | 65 | 0.250 |
Why?
| Cholesterol, HDL | 4 | 2022 | 199 | 0.250 |
Why?
| Cohort Studies | 14 | 2021 | 5117 | 0.250 |
Why?
| Autoimmunity | 5 | 2023 | 831 | 0.250 |
Why?
| Absorptiometry, Photon | 6 | 2022 | 229 | 0.240 |
Why?
| Life Style | 3 | 2024 | 431 | 0.240 |
Why?
| Middle Aged | 25 | 2023 | 27627 | 0.240 |
Why?
| Pilot Projects | 8 | 2021 | 1420 | 0.230 |
Why?
| Gastrointestinal Microbiome | 2 | 2021 | 548 | 0.230 |
Why?
| Lupus Nephritis | 1 | 2024 | 55 | 0.230 |
Why?
| Aftercare | 2 | 2022 | 194 | 0.230 |
Why?
| Follow-Up Studies | 11 | 2020 | 4596 | 0.230 |
Why?
| Androgens | 2 | 2022 | 168 | 0.230 |
Why?
| Hypertension | 2 | 2022 | 1203 | 0.230 |
Why?
| Turner Syndrome | 1 | 2023 | 50 | 0.230 |
Why?
| Neurodevelopmental Disorders | 2 | 2021 | 116 | 0.220 |
Why?
| Hyperoxia | 1 | 2024 | 97 | 0.220 |
Why?
| Ventricular Function, Left | 2 | 2016 | 468 | 0.220 |
Why?
| Glycemic Index | 1 | 2022 | 24 | 0.220 |
Why?
| Insulins | 1 | 2023 | 34 | 0.220 |
Why?
| Oxygen Consumption | 4 | 2017 | 586 | 0.220 |
Why?
| Pulmonary Surfactant-Associated Protein B | 1 | 2022 | 6 | 0.210 |
Why?
| Students | 2 | 2022 | 509 | 0.210 |
Why?
| Hypothalamic Neoplasms | 1 | 2022 | 10 | 0.210 |
Why?
| Enterovirus D, Human | 1 | 2023 | 76 | 0.210 |
Why?
| Hypothalamic Diseases | 1 | 2022 | 18 | 0.210 |
Why?
| United States | 15 | 2024 | 12557 | 0.210 |
Why?
| Cation Transport Proteins | 1 | 2022 | 99 | 0.210 |
Why?
| Lipoproteins, HDL | 3 | 2021 | 82 | 0.210 |
Why?
| C-Peptide | 3 | 2018 | 139 | 0.210 |
Why?
| Guideline Adherence | 2 | 2017 | 523 | 0.210 |
Why?
| HLA-DR Antigens | 1 | 2022 | 224 | 0.200 |
Why?
| Obesity, Abdominal | 2 | 2018 | 39 | 0.200 |
Why?
| Gender Dysphoria | 1 | 2021 | 14 | 0.200 |
Why?
| Ketosis | 1 | 2021 | 13 | 0.200 |
Why?
| Estradiol | 5 | 2023 | 476 | 0.200 |
Why?
| Exercise | 4 | 2023 | 1657 | 0.200 |
Why?
| Adrenal Hyperplasia, Congenital | 1 | 2021 | 29 | 0.200 |
Why?
| Autoantigens | 2 | 2021 | 397 | 0.200 |
Why?
| Reference Standards | 1 | 2021 | 176 | 0.200 |
Why?
| Schools | 2 | 2018 | 411 | 0.200 |
Why?
| Respiration, Artificial | 2 | 2022 | 545 | 0.200 |
Why?
| Disorders of Sex Development | 1 | 2021 | 37 | 0.200 |
Why?
| Adenosine Diphosphate | 2 | 2021 | 88 | 0.200 |
Why?
| Attentional Bias | 1 | 2021 | 10 | 0.200 |
Why?
| Pregnancy Outcome | 3 | 2021 | 349 | 0.200 |
Why?
| Lipid Metabolism | 3 | 2019 | 477 | 0.200 |
Why?
| Enterovirus Infections | 1 | 2023 | 164 | 0.190 |
Why?
| Supine Position | 1 | 2021 | 39 | 0.190 |
Why?
| Protein Precursors | 1 | 2021 | 126 | 0.190 |
Why?
| Kidney Tubules | 1 | 2021 | 128 | 0.190 |
Why?
| Fear | 2 | 2022 | 307 | 0.190 |
Why?
| Mood Disorders | 1 | 2021 | 119 | 0.190 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2022 | 156 | 0.190 |
Why?
| Drug Utilization Review | 2 | 2017 | 60 | 0.190 |
Why?
| Hyperinsulinism | 2 | 2019 | 108 | 0.190 |
Why?
| Desogestrel | 1 | 2020 | 41 | 0.190 |
Why?
| Pregnancy | 9 | 2024 | 5694 | 0.190 |
Why?
| Sex Chromosome Disorders | 1 | 2020 | 13 | 0.190 |
Why?
| Dyslipidemias | 1 | 2022 | 162 | 0.190 |
Why?
| HLA-DQ beta-Chains | 1 | 2020 | 61 | 0.180 |
Why?
| Sex Chromosome Aberrations | 1 | 2020 | 53 | 0.180 |
Why?
| Waist Circumference | 2 | 2019 | 130 | 0.180 |
Why?
| Celiac Disease | 1 | 2023 | 267 | 0.180 |
Why?
| Transgender Persons | 1 | 2022 | 135 | 0.180 |
Why?
| Heart Ventricles | 2 | 2016 | 727 | 0.180 |
Why?
| Sodium-Glucose Transporter 1 | 1 | 2019 | 12 | 0.180 |
Why?
| Glutamate Decarboxylase | 3 | 2022 | 159 | 0.180 |
Why?
| Oxygen | 2 | 2024 | 857 | 0.180 |
Why?
| Gastroparesis | 1 | 2019 | 10 | 0.180 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2024 | 1244 | 0.180 |
Why?
| RNA Interference | 1 | 2021 | 460 | 0.180 |
Why?
| Patient Dropouts | 1 | 2020 | 66 | 0.180 |
Why?
| Monitoring, Physiologic | 1 | 2022 | 272 | 0.180 |
Why?
| Cardiorespiratory Fitness | 2 | 2017 | 39 | 0.180 |
Why?
| Respiratory Tract Infections | 1 | 2023 | 331 | 0.180 |
Why?
| Aorta | 2 | 2019 | 367 | 0.180 |
Why?
| Lipoproteins | 2 | 2022 | 163 | 0.170 |
Why?
| Hip Fractures | 1 | 2020 | 79 | 0.170 |
Why?
| Treatment Outcome | 11 | 2021 | 9346 | 0.170 |
Why?
| Reproducibility of Results | 7 | 2024 | 2874 | 0.170 |
Why?
| Infant, Newborn | 9 | 2021 | 5256 | 0.170 |
Why?
| Severity of Illness Index | 4 | 2021 | 2674 | 0.170 |
Why?
| Focal Dermal Hypoplasia | 1 | 2019 | 6 | 0.170 |
Why?
| Peptides | 2 | 2023 | 879 | 0.170 |
Why?
| Monitoring, Ambulatory | 2 | 2016 | 84 | 0.170 |
Why?
| Iohexol | 2 | 2020 | 21 | 0.170 |
Why?
| Amino Acids | 2 | 2022 | 465 | 0.170 |
Why?
| Sleep Disorders, Circadian Rhythm | 1 | 2019 | 40 | 0.170 |
Why?
| Glomerulonephritis | 1 | 2019 | 60 | 0.170 |
Why?
| Failure to Thrive | 1 | 2019 | 31 | 0.170 |
Why?
| Osteoporosis, Postmenopausal | 1 | 2019 | 38 | 0.170 |
Why?
| Longitudinal Studies | 7 | 2020 | 2513 | 0.170 |
Why?
| Kidney Function Tests | 2 | 2022 | 164 | 0.170 |
Why?
| Taurine | 1 | 2019 | 46 | 0.170 |
Why?
| Personal Satisfaction | 1 | 2020 | 188 | 0.170 |
Why?
| Cystathionine beta-Synthase | 1 | 2019 | 60 | 0.170 |
Why?
| Prognosis | 7 | 2020 | 3443 | 0.170 |
Why?
| Brachial Artery | 2 | 2019 | 181 | 0.160 |
Why?
| Growth Disorders | 1 | 2019 | 77 | 0.160 |
Why?
| Homocystinuria | 1 | 2019 | 63 | 0.160 |
Why?
| Methyldopa | 1 | 2018 | 8 | 0.160 |
Why?
| Culturally Competent Care | 1 | 2019 | 53 | 0.160 |
Why?
| Gonadal Steroid Hormones | 1 | 2019 | 122 | 0.160 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 118 | 0.160 |
Why?
| Anxiety | 2 | 2021 | 846 | 0.160 |
Why?
| Cardiotonic Agents | 1 | 2018 | 127 | 0.160 |
Why?
| Cancellous Bone | 1 | 2017 | 21 | 0.160 |
Why?
| Sodium Bicarbonate | 1 | 2018 | 45 | 0.160 |
Why?
| Oxidative Phosphorylation | 2 | 2017 | 156 | 0.160 |
Why?
| Wounds and Injuries | 2 | 2016 | 772 | 0.160 |
Why?
| Aminopyridines | 1 | 2018 | 85 | 0.160 |
Why?
| Sex Characteristics | 3 | 2019 | 671 | 0.160 |
Why?
| Transplantation Conditioning | 1 | 2019 | 156 | 0.160 |
Why?
| Anxiety Disorders | 2 | 2021 | 309 | 0.150 |
Why?
| Twins, Dizygotic | 1 | 2018 | 182 | 0.150 |
Why?
| Medical Order Entry Systems | 1 | 2018 | 42 | 0.150 |
Why?
| T-Lymphocytes | 3 | 2023 | 1774 | 0.150 |
Why?
| Benzodioxoles | 1 | 2018 | 84 | 0.150 |
Why?
| Sex Factors | 6 | 2019 | 1781 | 0.150 |
Why?
| Prevalence | 5 | 2023 | 2326 | 0.150 |
Why?
| Interferon-gamma | 1 | 2021 | 737 | 0.150 |
Why?
| HLA-DQ Antigens | 1 | 2018 | 176 | 0.150 |
Why?
| Anti-Bacterial Agents | 2 | 2017 | 1517 | 0.150 |
Why?
| Cefoxitin | 1 | 2017 | 9 | 0.150 |
Why?
| Twins, Monozygotic | 1 | 2018 | 214 | 0.150 |
Why?
| Fluid Therapy | 2 | 2015 | 131 | 0.150 |
Why?
| Ceftriaxone | 1 | 2017 | 17 | 0.150 |
Why?
| Infant, Premature | 1 | 2021 | 480 | 0.150 |
Why?
| Metronidazole | 1 | 2017 | 21 | 0.150 |
Why?
| Surveys and Questionnaires | 5 | 2023 | 4709 | 0.150 |
Why?
| Depressive Disorder | 1 | 2020 | 333 | 0.150 |
Why?
| Aminophenols | 1 | 2018 | 112 | 0.150 |
Why?
| Blood Vessels | 1 | 2018 | 187 | 0.150 |
Why?
| Quinolones | 1 | 2018 | 98 | 0.150 |
Why?
| Antigen Presentation | 1 | 2018 | 194 | 0.150 |
Why?
| beta-Lactams | 1 | 2017 | 28 | 0.150 |
Why?
| Hospital Charges | 1 | 2016 | 42 | 0.150 |
Why?
| Head Protective Devices | 1 | 2016 | 17 | 0.150 |
Why?
| Antibody Formation | 1 | 2018 | 276 | 0.140 |
Why?
| Human Development | 1 | 2016 | 18 | 0.140 |
Why?
| Influenza, Human | 1 | 2022 | 555 | 0.140 |
Why?
| Menopause | 1 | 2019 | 266 | 0.140 |
Why?
| Acute Kidney Injury | 2 | 2021 | 709 | 0.140 |
Why?
| Luminescence | 1 | 2016 | 34 | 0.140 |
Why?
| Pneumonia | 1 | 2022 | 592 | 0.140 |
Why?
| Biodiversity | 1 | 2020 | 378 | 0.140 |
Why?
| Musculoskeletal Diseases | 1 | 2017 | 68 | 0.140 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2021 | 702 | 0.140 |
Why?
| Liver | 3 | 2019 | 1816 | 0.140 |
Why?
| Lipogenesis | 1 | 2016 | 66 | 0.140 |
Why?
| Skiing | 1 | 2016 | 39 | 0.140 |
Why?
| Mass Screening | 3 | 2018 | 1052 | 0.140 |
Why?
| Multiple Organ Failure | 1 | 2017 | 150 | 0.140 |
Why?
| Respiratory Function Tests | 1 | 2018 | 526 | 0.140 |
Why?
| Age Factors | 6 | 2020 | 2995 | 0.140 |
Why?
| Cholesterol, LDL | 2 | 2014 | 317 | 0.140 |
Why?
| Echocardiography | 2 | 2016 | 556 | 0.140 |
Why?
| Immunity, Cellular | 1 | 2018 | 270 | 0.140 |
Why?
| Hypogonadism | 1 | 2016 | 77 | 0.140 |
Why?
| Body Weight | 1 | 2020 | 934 | 0.140 |
Why?
| Melanoma | 1 | 2022 | 664 | 0.140 |
Why?
| Emotions | 1 | 2021 | 495 | 0.140 |
Why?
| Up-Regulation | 2 | 2016 | 872 | 0.140 |
Why?
| Fatty Acids | 1 | 2019 | 407 | 0.140 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 280 | 0.140 |
Why?
| Milk, Human | 1 | 2017 | 145 | 0.140 |
Why?
| C-Reactive Protein | 1 | 2018 | 364 | 0.130 |
Why?
| Blood Pressure | 3 | 2019 | 1664 | 0.130 |
Why?
| Deuterium | 1 | 2015 | 78 | 0.130 |
Why?
| Neutropenia | 1 | 2016 | 133 | 0.130 |
Why?
| Exanthema | 1 | 2016 | 77 | 0.130 |
Why?
| Leptin | 1 | 2017 | 231 | 0.130 |
Why?
| Appendicitis | 1 | 2017 | 125 | 0.130 |
Why?
| Catheters, Indwelling | 1 | 2015 | 82 | 0.130 |
Why?
| Mothers | 2 | 2021 | 683 | 0.130 |
Why?
| Decision Support Systems, Clinical | 1 | 2018 | 178 | 0.130 |
Why?
| Anti-Infective Agents | 1 | 2018 | 227 | 0.130 |
Why?
| Diarrhea | 1 | 2016 | 181 | 0.130 |
Why?
| Hyperandrogenism | 1 | 2015 | 14 | 0.130 |
Why?
| Antimicrobial Stewardship | 1 | 2017 | 96 | 0.130 |
Why?
| Craniocerebral Trauma | 1 | 2016 | 146 | 0.130 |
Why?
| Quality of Life | 3 | 2024 | 2369 | 0.130 |
Why?
| Cystatin C | 4 | 2015 | 69 | 0.130 |
Why?
| Renal Insufficiency, Chronic | 3 | 2016 | 590 | 0.130 |
Why?
| Registries | 3 | 2016 | 1810 | 0.130 |
Why?
| Pulse Wave Analysis | 3 | 2021 | 216 | 0.120 |
Why?
| Aircraft | 1 | 2014 | 28 | 0.120 |
Why?
| Linear Models | 4 | 2019 | 827 | 0.120 |
Why?
| Patient Acceptance of Health Care | 2 | 2019 | 687 | 0.120 |
Why?
| Peritoneal Dialysis | 1 | 2015 | 85 | 0.120 |
Why?
| Injury Severity Score | 1 | 2016 | 528 | 0.120 |
Why?
| Double-Blind Method | 4 | 2021 | 1687 | 0.120 |
Why?
| Dietary Supplements | 1 | 2018 | 467 | 0.120 |
Why?
| Transportation of Patients | 1 | 2014 | 49 | 0.120 |
Why?
| Bacterial Infections | 1 | 2016 | 227 | 0.120 |
Why?
| Propensity Score | 3 | 2021 | 242 | 0.120 |
Why?
| Hypoxia | 1 | 2020 | 963 | 0.120 |
Why?
| Diabetic Retinopathy | 1 | 2016 | 160 | 0.120 |
Why?
| Bacteria | 1 | 2020 | 757 | 0.120 |
Why?
| Brain Neoplasms | 1 | 2022 | 1023 | 0.120 |
Why?
| Decision Making | 1 | 2020 | 809 | 0.120 |
Why?
| Incidence | 5 | 2021 | 2424 | 0.120 |
Why?
| Goals | 1 | 2015 | 167 | 0.120 |
Why?
| Telemedicine | 1 | 2022 | 668 | 0.110 |
Why?
| Heart Atria | 1 | 2014 | 112 | 0.110 |
Why?
| Mental Disorders | 1 | 2021 | 939 | 0.110 |
Why?
| Sleep Wake Disorders | 1 | 2016 | 241 | 0.110 |
Why?
| Heart Defects, Congenital | 1 | 2019 | 703 | 0.110 |
Why?
| Practice Guidelines as Topic | 2 | 2017 | 1440 | 0.110 |
Why?
| Critical Care | 1 | 2017 | 493 | 0.110 |
Why?
| Chitinase-3-Like Protein 1 | 2 | 2022 | 17 | 0.110 |
Why?
| Hemodynamics | 3 | 2022 | 1004 | 0.110 |
Why?
| RNA, Messenger | 2 | 2019 | 2661 | 0.110 |
Why?
| Acetaminophen | 1 | 2015 | 244 | 0.110 |
Why?
| Referral and Consultation | 1 | 2017 | 648 | 0.110 |
Why?
| Histidine | 2 | 2022 | 63 | 0.110 |
Why?
| Health Personnel | 1 | 2018 | 588 | 0.110 |
Why?
| Models, Biological | 2 | 2016 | 1715 | 0.110 |
Why?
| Glycation End Products, Advanced | 3 | 2018 | 67 | 0.110 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2021 | 508 | 0.110 |
Why?
| Models, Theoretical | 1 | 2015 | 556 | 0.100 |
Why?
| Lung Diseases | 1 | 2018 | 718 | 0.100 |
Why?
| Immunity, Innate | 1 | 2017 | 745 | 0.100 |
Why?
| Burns | 1 | 2015 | 247 | 0.100 |
Why?
| Thiazolidinediones | 1 | 2012 | 146 | 0.100 |
Why?
| Sepsis | 1 | 2017 | 531 | 0.100 |
Why?
| Aneuploidy | 2 | 2022 | 88 | 0.100 |
Why?
| Risk Assessment | 4 | 2022 | 3057 | 0.090 |
Why?
| Seroepidemiologic Studies | 2 | 2023 | 146 | 0.090 |
Why?
| Pregnant Women | 2 | 2021 | 132 | 0.090 |
Why?
| Risk | 3 | 2019 | 854 | 0.090 |
Why?
| Salicylates | 1 | 2010 | 32 | 0.090 |
Why?
| Quality Improvement | 1 | 2018 | 963 | 0.090 |
Why?
| Pandemics | 3 | 2024 | 1355 | 0.090 |
Why?
| Gene Expression Regulation | 1 | 2019 | 2446 | 0.090 |
Why?
| Multivariate Analysis | 4 | 2016 | 1474 | 0.090 |
Why?
| Prodrugs | 1 | 2010 | 44 | 0.090 |
Why?
| Ketone Bodies | 2 | 2021 | 17 | 0.090 |
Why?
| Asthma | 1 | 2023 | 2159 | 0.090 |
Why?
| Weight Gain | 2 | 2024 | 493 | 0.090 |
Why?
| Educational Status | 2 | 2022 | 437 | 0.090 |
Why?
| Haplotypes | 2 | 2022 | 473 | 0.090 |
Why?
| Sex Hormone-Binding Globulin | 2 | 2019 | 49 | 0.090 |
Why?
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2009 | 11 | 0.090 |
Why?
| Albumins | 2 | 2022 | 100 | 0.090 |
Why?
| Physical Education and Training | 1 | 2009 | 62 | 0.090 |
Why?
| Receptors, Antigen, T-Cell | 2 | 2023 | 634 | 0.090 |
Why?
| Insulin Antibodies | 2 | 2022 | 101 | 0.080 |
Why?
| Communicable Disease Control | 2 | 2021 | 72 | 0.080 |
Why?
| Mice, Inbred NOD | 2 | 2022 | 574 | 0.080 |
Why?
| Alleles | 2 | 2022 | 832 | 0.080 |
Why?
| Odds Ratio | 2 | 2021 | 996 | 0.080 |
Why?
| Bone Diseases, Metabolic | 2 | 2019 | 60 | 0.080 |
Why?
| Melatonin | 2 | 2019 | 109 | 0.080 |
Why?
| Problem Solving | 1 | 2009 | 145 | 0.080 |
Why?
| Emergency Medical Services | 1 | 2014 | 589 | 0.070 |
Why?
| Parents | 3 | 2024 | 1212 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2021 | 736 | 0.070 |
Why?
| Program Development | 1 | 2009 | 357 | 0.070 |
Why?
| Inpatients | 2 | 2024 | 389 | 0.070 |
Why?
| Forced Expiratory Volume | 2 | 2018 | 520 | 0.070 |
Why?
| Logistic Models | 2 | 2021 | 1901 | 0.070 |
Why?
| Self Care | 1 | 2009 | 357 | 0.070 |
Why?
| Patient Discharge | 2 | 2022 | 794 | 0.070 |
Why?
| Hospitalization | 3 | 2024 | 1785 | 0.070 |
Why?
| Hydrogen-Ion Concentration | 2 | 2018 | 536 | 0.070 |
Why?
| Databases, Factual | 2 | 2021 | 1231 | 0.070 |
Why?
| Academic Medical Centers | 2 | 2019 | 422 | 0.070 |
Why?
| Mice | 4 | 2023 | 15528 | 0.060 |
Why?
| Calcium | 2 | 2022 | 1171 | 0.060 |
Why?
| Learning | 1 | 2009 | 374 | 0.060 |
Why?
| Weight Loss | 2 | 2024 | 658 | 0.060 |
Why?
| Random Allocation | 2 | 2018 | 349 | 0.060 |
Why?
| Motor Activity | 1 | 2009 | 666 | 0.060 |
Why?
| Magnetic Resonance Imaging | 3 | 2021 | 3175 | 0.060 |
Why?
| Canagliflozin | 1 | 2023 | 11 | 0.060 |
Why?
| Needs Assessment | 2 | 2016 | 327 | 0.060 |
Why?
| Cyclophosphamide | 1 | 2024 | 222 | 0.060 |
Why?
| Survival Analysis | 2 | 2020 | 1267 | 0.060 |
Why?
| Phenotype | 2 | 2023 | 3004 | 0.060 |
Why?
| Glucagon | 1 | 2023 | 98 | 0.060 |
Why?
| Testosterone Congeners | 1 | 2022 | 8 | 0.060 |
Why?
| Epidermal Growth Factor | 1 | 2023 | 173 | 0.060 |
Why?
| Health Promotion | 1 | 2009 | 691 | 0.050 |
Why?
| Transglutaminases | 1 | 2023 | 143 | 0.050 |
Why?
| Haploinsufficiency | 1 | 2022 | 47 | 0.050 |
Why?
| Zinc Transporter 8 | 1 | 2022 | 63 | 0.050 |
Why?
| Germany | 1 | 2022 | 89 | 0.050 |
Why?
| Malates | 1 | 2022 | 7 | 0.050 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2023 | 104 | 0.050 |
Why?
| Respiratory System | 1 | 2023 | 141 | 0.050 |
Why?
| Intensive Care Units | 2 | 2017 | 635 | 0.050 |
Why?
| Fumarates | 1 | 2022 | 12 | 0.050 |
Why?
| Sodium | 1 | 2023 | 200 | 0.050 |
Why?
| Threonine | 1 | 2022 | 45 | 0.050 |
Why?
| Carboxylic Acids | 1 | 2022 | 30 | 0.050 |
Why?
| Kidney Glomerulus | 1 | 2023 | 133 | 0.050 |
Why?
| Delphi Technique | 1 | 2023 | 164 | 0.050 |
Why?
| Length of Stay | 2 | 2017 | 1031 | 0.050 |
Why?
| HLA-DR4 Antigen | 1 | 2022 | 75 | 0.050 |
Why?
| Lipocalin-2 | 1 | 2022 | 64 | 0.050 |
Why?
| Asymptomatic Diseases | 1 | 2022 | 81 | 0.050 |
Why?
| Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.050 |
Why?
| HLA-DR3 Antigen | 1 | 2022 | 77 | 0.050 |
Why?
| Predictive Value of Tests | 2 | 2018 | 1868 | 0.050 |
Why?
| Phenylalanine | 1 | 2022 | 66 | 0.050 |
Why?
| Respiration | 1 | 2022 | 184 | 0.050 |
Why?
| Mice, SCID | 1 | 2022 | 333 | 0.050 |
Why?
| Phosphocreatine | 1 | 2021 | 37 | 0.050 |
Why?
| 3-Hydroxybutyric Acid | 1 | 2021 | 15 | 0.050 |
Why?
| Chemokine CCL2 | 1 | 2022 | 126 | 0.050 |
Why?
| Depression | 2 | 2023 | 1137 | 0.050 |
Why?
| Psychotherapy | 1 | 2024 | 177 | 0.050 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 965 | 0.050 |
Why?
| HLA-A2 Antigen | 1 | 2021 | 39 | 0.050 |
Why?
| Leucine | 1 | 2022 | 117 | 0.050 |
Why?
| Tamoxifen | 1 | 2022 | 198 | 0.050 |
Why?
| Oxidative Stress | 2 | 2019 | 1179 | 0.050 |
Why?
| Dyspnea | 1 | 2023 | 201 | 0.050 |
Why?
| Glycine | 1 | 2022 | 162 | 0.050 |
Why?
| Cognition | 1 | 2009 | 1025 | 0.050 |
Why?
| Ketones | 1 | 2021 | 45 | 0.050 |
Why?
| Breath Tests | 1 | 2021 | 90 | 0.050 |
Why?
| Benchmarking | 1 | 2022 | 172 | 0.050 |
Why?
| Tryptophan | 1 | 2022 | 139 | 0.050 |
Why?
| Bacteroidetes | 1 | 2021 | 22 | 0.050 |
Why?
| Healthy Volunteers | 1 | 2022 | 201 | 0.050 |
Why?
| Firmicutes | 1 | 2021 | 20 | 0.050 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2022 | 193 | 0.050 |
Why?
| Morbidity | 1 | 2022 | 296 | 0.050 |
Why?
| Marital Status | 1 | 2021 | 43 | 0.050 |
Why?
| Behavior Therapy | 1 | 2023 | 237 | 0.050 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 311 | 0.050 |
Why?
| Contraceptive Devices, Female | 1 | 2020 | 9 | 0.050 |
Why?
| p-Aminohippuric Acid | 1 | 2020 | 8 | 0.050 |
Why?
| Disease Outbreaks | 1 | 2023 | 322 | 0.050 |
Why?
| Health Resources | 1 | 2022 | 132 | 0.050 |
Why?
| Maternal Age | 1 | 2021 | 122 | 0.050 |
Why?
| HLA Antigens | 1 | 2022 | 230 | 0.050 |
Why?
| Furosemide | 1 | 2020 | 35 | 0.050 |
Why?
| Facial Expression | 1 | 2021 | 62 | 0.050 |
Why?
| Animals | 5 | 2023 | 33399 | 0.050 |
Why?
| Interleukin-18 | 1 | 2022 | 229 | 0.050 |
Why?
| Insulin Glargine | 1 | 2020 | 73 | 0.050 |
Why?
| Karyotyping | 1 | 2020 | 102 | 0.050 |
Why?
| Consensus | 1 | 2023 | 534 | 0.050 |
Why?
| Drug Implants | 1 | 2020 | 72 | 0.050 |
Why?
| Computer Systems | 1 | 2020 | 47 | 0.050 |
Why?
| Child Behavior Disorders | 1 | 2021 | 129 | 0.050 |
Why?
| Natriuresis | 1 | 2019 | 14 | 0.050 |
Why?
| Calibration | 1 | 2020 | 135 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2024 | 683 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 421 | 0.040 |
Why?
| Sexual Maturation | 1 | 2019 | 51 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 452 | 0.040 |
Why?
| Device Removal | 1 | 2020 | 127 | 0.040 |
Why?
| Renin-Angiotensin System | 1 | 2019 | 82 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2023 | 542 | 0.040 |
Why?
| Premenopause | 1 | 2019 | 108 | 0.040 |
Why?
| Adenosine Triphosphate | 1 | 2021 | 439 | 0.040 |
Why?
| Radius | 1 | 2019 | 33 | 0.040 |
Why?
| Reference Values | 1 | 2020 | 775 | 0.040 |
Why?
| Calorimetry, Indirect | 1 | 2019 | 72 | 0.040 |
Why?
| Reproductive Health | 1 | 2019 | 68 | 0.040 |
Why?
| Methylation | 1 | 2019 | 204 | 0.040 |
Why?
| Survivors | 1 | 2022 | 418 | 0.040 |
Why?
| Carnitine | 1 | 2019 | 65 | 0.040 |
Why?
| Carotid Intima-Media Thickness | 1 | 2018 | 68 | 0.040 |
Why?
| Prenatal Diagnosis | 1 | 2020 | 168 | 0.040 |
Why?
| Homocysteine | 1 | 2019 | 137 | 0.040 |
Why?
| Wakefulness | 1 | 2019 | 128 | 0.040 |
Why?
| Developmental Disabilities | 1 | 2021 | 247 | 0.040 |
Why?
| RNA, Ribosomal, 16S | 1 | 2021 | 514 | 0.040 |
Why?
| Feces | 1 | 2021 | 396 | 0.040 |
Why?
| Microscopy, Polarization | 1 | 2018 | 33 | 0.040 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 36 | 0.040 |
Why?
| Intra-Abdominal Fat | 1 | 2018 | 98 | 0.040 |
Why?
| Gestational Age | 1 | 2021 | 765 | 0.040 |
Why?
| Communication Barriers | 1 | 2019 | 94 | 0.040 |
Why?
| Saliva | 1 | 2019 | 188 | 0.040 |
Why?
| Biopsy | 1 | 2022 | 1079 | 0.040 |
Why?
| Psychiatric Status Rating Scales | 1 | 2020 | 499 | 0.040 |
Why?
| Homozygote | 1 | 2018 | 190 | 0.040 |
Why?
| Organizational Innovation | 1 | 2019 | 138 | 0.040 |
Why?
| Age of Onset | 1 | 2019 | 467 | 0.040 |
Why?
| Osmolar Concentration | 1 | 2018 | 185 | 0.040 |
Why?
| Population Surveillance | 1 | 2021 | 413 | 0.040 |
Why?
| Cell Death | 1 | 2019 | 339 | 0.040 |
Why?
| Receptors, Lipoprotein | 1 | 1997 | 3 | 0.040 |
Why?
| Pyomyositis | 1 | 2017 | 14 | 0.040 |
Why?
| Vital Capacity | 1 | 2018 | 260 | 0.040 |
Why?
| Phosphorus Isotopes | 1 | 2017 | 9 | 0.040 |
Why?
| Aged | 4 | 2021 | 19661 | 0.040 |
Why?
| Early Medical Intervention | 1 | 2018 | 56 | 0.040 |
Why?
| Proteome | 1 | 2021 | 353 | 0.040 |
Why?
| Drug Combinations | 1 | 2018 | 291 | 0.040 |
Why?
| Tibia | 1 | 2019 | 177 | 0.040 |
Why?
| Immunotherapy | 1 | 2021 | 493 | 0.040 |
Why?
| Tomography, X-Ray Computed | 2 | 2019 | 2436 | 0.040 |
Why?
| RNA | 1 | 2023 | 833 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2019 | 331 | 0.040 |
Why?
| Siblings | 1 | 2018 | 235 | 0.040 |
Why?
| Anthropometry | 1 | 2017 | 194 | 0.040 |
Why?
| Diseases in Twins | 1 | 2018 | 181 | 0.040 |
Why?
| Central Venous Catheters | 1 | 2017 | 42 | 0.040 |
Why?
| Voluntary Health Agencies | 1 | 2016 | 6 | 0.040 |
Why?
| Glucose Intolerance | 1 | 2018 | 139 | 0.040 |
Why?
| Organ Dysfunction Scores | 1 | 2017 | 39 | 0.040 |
Why?
| Abdominal Abscess | 1 | 2017 | 27 | 0.040 |
Why?
| Lymphocyte Count | 1 | 2017 | 136 | 0.040 |
Why?
| Arthritis, Infectious | 1 | 2017 | 52 | 0.040 |
Why?
| Abscess | 1 | 2017 | 75 | 0.040 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 210 | 0.040 |
Why?
| Drug Substitution | 1 | 2017 | 46 | 0.040 |
Why?
| Sertoli Cells | 1 | 2016 | 25 | 0.040 |
Why?
| Medical Records | 1 | 2017 | 163 | 0.040 |
Why?
| Appendectomy | 1 | 2017 | 73 | 0.040 |
Why?
| Cost Savings | 1 | 2017 | 77 | 0.040 |
Why?
| Twins | 1 | 2018 | 247 | 0.040 |
Why?
| Blood Banks | 1 | 2016 | 43 | 0.040 |
Why?
| Critical Illness | 1 | 2022 | 663 | 0.040 |
Why?
| Inhibins | 1 | 2016 | 46 | 0.040 |
Why?
| Drug Resistance | 1 | 2017 | 167 | 0.040 |
Why?
| Drug Utilization | 1 | 2017 | 169 | 0.040 |
Why?
| History, 21st Century | 1 | 2017 | 170 | 0.040 |
Why?
| Vascular Capacitance | 1 | 2016 | 4 | 0.040 |
Why?
| Lipids | 2 | 2010 | 608 | 0.040 |
Why?
| Environment | 1 | 2018 | 346 | 0.040 |
Why?
| Anti-Mullerian Hormone | 1 | 2016 | 51 | 0.040 |
Why?
| Analysis of Variance | 1 | 2019 | 1295 | 0.040 |
Why?
| Hip Joint | 1 | 2017 | 144 | 0.040 |
Why?
| Delayed Diagnosis | 1 | 2016 | 79 | 0.030 |
Why?
| Hypertrophy | 1 | 2016 | 121 | 0.030 |
Why?
| Diastole | 1 | 2016 | 145 | 0.030 |
Why?
| Outpatient Clinics, Hospital | 1 | 2016 | 79 | 0.030 |
Why?
| Access to Information | 1 | 2016 | 53 | 0.030 |
Why?
| Lactation | 1 | 2017 | 160 | 0.030 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2016 | 12 | 0.030 |
Why?
| Consumer Health Information | 1 | 2016 | 48 | 0.030 |
Why?
| Systole | 1 | 2016 | 168 | 0.030 |
Why?
| Area Under Curve | 1 | 2016 | 296 | 0.030 |
Why?
| Fever | 1 | 2017 | 283 | 0.030 |
Why?
| Medicaid | 1 | 2020 | 411 | 0.030 |
Why?
| Osteomyelitis | 1 | 2017 | 110 | 0.030 |
Why?
| Chronic Disease | 1 | 2022 | 1637 | 0.030 |
Why?
| Luteinizing Hormone | 1 | 2016 | 173 | 0.030 |
Why?
| Metabolome | 1 | 2019 | 296 | 0.030 |
Why?
| Lumbar Vertebrae | 1 | 2017 | 215 | 0.030 |
Why?
| Dialysis Solutions | 1 | 2015 | 25 | 0.030 |
Why?
| Equipment Failure | 1 | 2016 | 114 | 0.030 |
Why?
| Administration, Intravenous | 1 | 2016 | 136 | 0.030 |
Why?
| Statistics as Topic | 1 | 2016 | 307 | 0.030 |
Why?
| Echocardiography, Doppler | 1 | 2016 | 95 | 0.030 |
Why?
| Models, Statistical | 1 | 2019 | 636 | 0.030 |
Why?
| Caregivers | 1 | 2022 | 709 | 0.030 |
Why?
| Mitochondria | 1 | 2021 | 786 | 0.030 |
Why?
| Stillbirth | 1 | 2015 | 58 | 0.030 |
Why?
| Follicle Stimulating Hormone | 1 | 2016 | 216 | 0.030 |
Why?
| Communicable Diseases | 1 | 2017 | 132 | 0.030 |
Why?
| Genetic Testing | 1 | 2018 | 389 | 0.030 |
Why?
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 288 | 0.030 |
Why?
| Peritonitis | 1 | 2015 | 79 | 0.030 |
Why?
| Guidelines as Topic | 1 | 2017 | 262 | 0.030 |
Why?
| Photoplethysmography | 1 | 2015 | 19 | 0.030 |
Why?
| Body Surface Area | 1 | 2015 | 28 | 0.030 |
Why?
| Drug Monitoring | 1 | 2016 | 187 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 230 | 0.030 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2021 | 985 | 0.030 |
Why?
| Delivery, Obstetric | 1 | 2015 | 125 | 0.030 |
Why?
| Osteoporosis | 1 | 2017 | 229 | 0.030 |
Why?
| Regional Blood Flow | 1 | 2016 | 418 | 0.030 |
Why?
| Apolipoproteins | 1 | 2014 | 40 | 0.030 |
Why?
| Cross-Over Studies | 1 | 2016 | 456 | 0.030 |
Why?
| Acute Disease | 1 | 2017 | 941 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 175 | 0.030 |
Why?
| Blood Pressure Determination | 1 | 2015 | 133 | 0.030 |
Why?
| Health Care Surveys | 1 | 2016 | 546 | 0.030 |
Why?
| Muscle Strength | 1 | 2017 | 283 | 0.030 |
Why?
| Atrial Function, Left | 1 | 2014 | 7 | 0.030 |
Why?
| Stress, Mechanical | 1 | 2016 | 443 | 0.030 |
Why?
| Ventricular Dysfunction | 1 | 2014 | 15 | 0.030 |
Why?
| RNA-Binding Proteins | 1 | 1997 | 371 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2017 | 554 | 0.030 |
Why?
| Breakfast | 1 | 2014 | 17 | 0.030 |
Why?
| Clinical Decision-Making | 1 | 2016 | 277 | 0.030 |
Why?
| Metabolomics | 1 | 2019 | 550 | 0.030 |
Why?
| Dried Blood Spot Testing | 1 | 2014 | 68 | 0.030 |
Why?
| Administration, Oral | 1 | 2016 | 756 | 0.030 |
Why?
| Breast Feeding | 1 | 2017 | 386 | 0.030 |
Why?
| Hypertrophy, Left Ventricular | 1 | 2014 | 107 | 0.030 |
Why?
| Prenatal Care | 1 | 2015 | 252 | 0.030 |
Why?
| Exercise Test | 1 | 2016 | 551 | 0.030 |
Why?
| Point-of-Care Systems | 1 | 2015 | 151 | 0.030 |
Why?
| Sensitivity and Specificity | 1 | 2018 | 1795 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1125 | 0.030 |
Why?
| Biomechanical Phenomena | 1 | 2016 | 683 | 0.030 |
Why?
| Carrier Proteins | 1 | 1997 | 726 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 185 | 0.030 |
Why?
| Fractures, Bone | 1 | 2018 | 380 | 0.030 |
Why?
| Child Development | 1 | 2017 | 410 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 2025 | 0.030 |
Why?
| Cholesterol | 1 | 2014 | 375 | 0.030 |
Why?
| Laparoscopy | 1 | 2017 | 418 | 0.030 |
Why?
| Quality of Health Care | 1 | 2017 | 586 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2016 | 1129 | 0.030 |
Why?
| Outpatients | 1 | 2015 | 325 | 0.030 |
Why?
| Internet | 1 | 2016 | 633 | 0.030 |
Why?
| Patient Readmission | 1 | 2017 | 633 | 0.030 |
Why?
| Patient Compliance | 1 | 2015 | 537 | 0.030 |
Why?
| DNA | 1 | 2018 | 1388 | 0.020 |
Why?
| Pediatrics | 1 | 2019 | 985 | 0.020 |
Why?
| Treatment Failure | 1 | 2012 | 341 | 0.020 |
Why?
| Societies, Medical | 1 | 2015 | 703 | 0.020 |
Why?
| Biomedical Research | 1 | 2016 | 612 | 0.020 |
Why?
| Health Services Accessibility | 1 | 2016 | 781 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 2275 | 0.020 |
Why?
| Social Marketing | 1 | 2009 | 14 | 0.020 |
Why?
| Cytokines | 1 | 2017 | 1900 | 0.020 |
Why?
| Physical Examination | 1 | 2010 | 243 | 0.020 |
Why?
| Tinnitus | 1 | 2010 | 61 | 0.020 |
Why?
| Primary Health Care | 1 | 2019 | 1560 | 0.020 |
Why?
| Confidence Intervals | 1 | 2009 | 324 | 0.020 |
Why?
| Inflammation | 1 | 2019 | 2571 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2010 | 187 | 0.020 |
Why?
| Mutation | 1 | 2018 | 3457 | 0.020 |
Why?
| Heart Rate | 1 | 2009 | 729 | 0.020 |
Why?
| Program Evaluation | 1 | 2009 | 845 | 0.020 |
Why?
| Emergency Service, Hospital | 1 | 2015 | 1864 | 0.010 |
Why?
| Curriculum | 1 | 2009 | 910 | 0.010 |
Why?
| Lipoproteins, HDL3 | 1 | 1997 | 1 | 0.010 |
Why?
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 1997 | 2 | 0.010 |
Why?
| Blotting, Northern | 1 | 1997 | 194 | 0.010 |
Why?
| CHO Cells | 1 | 1997 | 143 | 0.010 |
Why?
| COS Cells | 1 | 1997 | 184 | 0.010 |
Why?
| Cricetinae | 1 | 1997 | 263 | 0.010 |
Why?
| Antigens, Surface | 1 | 1997 | 156 | 0.010 |
Why?
| Sequence Alignment | 1 | 1997 | 336 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1997 | 372 | 0.010 |
Why?
| Cell Adhesion Molecules | 1 | 1997 | 180 | 0.010 |
Why?
| Glycoproteins | 1 | 1997 | 319 | 0.010 |
Why?
| Transfection | 1 | 1997 | 890 | 0.010 |
Why?
| Base Sequence | 1 | 1997 | 2160 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1997 | 2073 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1997 | 2873 | 0.010 |
Why?
| Rats | 1 | 1997 | 5394 | 0.010 |
Why?
|
|
Pyle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|